Radiotheranostics Market Size, Share, Growth, Analysis, 2034

Download Free Sample

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Radiotheranostics Market Size Analysis

Global Radiotheranostics Market Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value

North America Market Analysis

Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value
U.S.
1. By Radioisotope
  1. Introduction
    1. Radioisotope By Value
  2. Iodine-131
    1. By Value
  3. Iodine-123
    1. By Value
  4. Gallium-68
    1. By Value
  5. Lutetium-177
    1. By Value
  6. 18F with Y-90
    1. By Value
  7. Others
    1. By Value
2. By Approach
  1. Introduction
    1. Approach By Value
  2. Targeted Therapeutic
    1. By Value
  3. Targeted Diagnostic
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Thyroid Cancer
    1. By Value
  4. Neuroendocrine Tumor
    1. By Value
  5. Hepatocellular Carcinoma
    1. By Value
  6. Prostate Cancer
    1. By Value
  7. Others
    1. By Value
    2. Neurological Disorders
      1. Neurological Disorders By Value
    3. Arthritis
      1. Arthritis By Value
    4. Others
      1. Others By Value
Canada

Europe Market Analysis

Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value
U.K.
1. By Radioisotope
  1. Introduction
    1. Radioisotope By Value
  2. Iodine-131
    1. By Value
  3. Iodine-123
    1. By Value
  4. Gallium-68
    1. By Value
  5. Lutetium-177
    1. By Value
  6. 18F with Y-90
    1. By Value
  7. Others
    1. By Value
2. By Approach
  1. Introduction
    1. Approach By Value
  2. Targeted Therapeutic
    1. By Value
  3. Targeted Diagnostic
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Thyroid Cancer
    1. By Value
  4. Neuroendocrine Tumor
    1. By Value
  5. Hepatocellular Carcinoma
    1. By Value
  6. Prostate Cancer
    1. By Value
  7. Others
    1. By Value
    2. Neurological Disorders
      1. Neurological Disorders By Value
    3. Arthritis
      1. Arthritis By Value
    4. Others
      1. Others By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value
China
1. By Radioisotope
  1. Introduction
    1. Radioisotope By Value
  2. Iodine-131
    1. By Value
  3. Iodine-123
    1. By Value
  4. Gallium-68
    1. By Value
  5. Lutetium-177
    1. By Value
  6. 18F with Y-90
    1. By Value
  7. Others
    1. By Value
2. By Approach
  1. Introduction
    1. Approach By Value
  2. Targeted Therapeutic
    1. By Value
  3. Targeted Diagnostic
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Thyroid Cancer
    1. By Value
  4. Neuroendocrine Tumor
    1. By Value
  5. Hepatocellular Carcinoma
    1. By Value
  6. Prostate Cancer
    1. By Value
  7. Others
    1. By Value
    2. Neurological Disorders
      1. Neurological Disorders By Value
    3. Arthritis
      1. Arthritis By Value
    4. Others
      1. Others By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value
UAE
1. By Radioisotope
  1. Introduction
    1. Radioisotope By Value
  2. Iodine-131
    1. By Value
  3. Iodine-123
    1. By Value
  4. Gallium-68
    1. By Value
  5. Lutetium-177
    1. By Value
  6. 18F with Y-90
    1. By Value
  7. Others
    1. By Value
2. By Approach
  1. Introduction
    1. Approach By Value
  2. Targeted Therapeutic
    1. By Value
  3. Targeted Diagnostic
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Thyroid Cancer
    1. By Value
  4. Neuroendocrine Tumor
    1. By Value
  5. Hepatocellular Carcinoma
    1. By Value
  6. Prostate Cancer
    1. By Value
  7. Others
    1. By Value
    2. Neurological Disorders
      1. Neurological Disorders By Value
    3. Arthritis
      1. Arthritis By Value
    4. Others
      1. Others By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Radioisotope
1. Introduction
  1. Radioisotope By Value
2. Iodine-131
  1. By Value
3. Iodine-123
  1. By Value
4. Gallium-68
  1. By Value
5. Lutetium-177
  1. By Value
6. 18F with Y-90
  1. By Value
7. Others
  1. By Value
By Approach
1. Introduction
  1. Approach By Value
2. Targeted Therapeutic
  1. By Value
3. Targeted Diagnostic
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Oncology
  1. By Value
3. Thyroid Cancer
  1. By Value
4. Neuroendocrine Tumor
  1. By Value
5. Hepatocellular Carcinoma
  1. By Value
6. Prostate Cancer
  1. By Value
7. Others
  1. By Value
  2. Neurological Disorders
    1. Neurological Disorders By Value
  3. Arthritis
    1. Arthritis By Value
  4. Others
    1. Others By Value
Brazil
1. By Radioisotope
  1. Introduction
    1. Radioisotope By Value
  2. Iodine-131
    1. By Value
  3. Iodine-123
    1. By Value
  4. Gallium-68
    1. By Value
  5. Lutetium-177
    1. By Value
  6. 18F with Y-90
    1. By Value
  7. Others
    1. By Value
2. By Approach
  1. Introduction
    1. Approach By Value
  2. Targeted Therapeutic
    1. By Value
  3. Targeted Diagnostic
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Oncology
    1. By Value
  3. Thyroid Cancer
    1. By Value
  4. Neuroendocrine Tumor
    1. By Value
  5. Hepatocellular Carcinoma
    1. By Value
  6. Prostate Cancer
    1. By Value
  7. Others
    1. By Value
    2. Neurological Disorders
      1. Neurological Disorders By Value
    3. Arthritis
      1. Arthritis By Value
    4. Others
      1. Others By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Radiotheranostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Novartis AG (Switzerland)
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Bayer AG (Germany)
Curium Pharma (France)
Telix Pharmaceuticals (Australia)
ITM Isotope Technologies Munich SE (Germany)
Lantheus Holdings (US)
POINT Biopharma Global Inc. (US)
Fusion Pharmaceuticals (Canada)
Actinium Pharmaceuticals (US)
Radiopharm Theranostics (Australia)
Clarity Pharmaceuticals (Australia)
Perspective Therapeutics (US)
GE HealthCare (US)
SHINE Technologies (US)
NorthStar Medical Radioisotopes (US)
RadioMedix Inc. (US)

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment

Appendix

Discussion Guide
Customization Options
Related Reports

Disclaimer

Get This Report

Our Clients:

Hindustan National Glass & Industries Limited

Table Of Content

Download Free Sample

Dhanashri B

Senior Research Associate